Requirements

Digital opinion leaders are out of scope for this product (OQ-21). No social-media tracking, no digital-opinion-leader view, no platform connector and no verification that an online voice is a clinician. This is a decision rather than a delay: a 2026 study found the most influential voices about one drug were mostly non-medical accounts, and a 2024 study found follower counts unreliable for finding opinion leaders. A caller reaching for this is told the product does not do it, not that an answer is pending.

Dropped by OQ-21. The answer went the other way, so nothing here is waiting on anybody and nothing arrives later.

The requirement asked for adverse events to be detected in free-text insights. There is no free text to detect them in: insight capture is pick-lists only (OQ-24), and the fixed category list carries a safety item that opens the customer's own safety reporting page while this product stores no side-effect content (NP-08). The requirement is replaced rather than deferred, which is why a caller is told no instead of later. SEC-06 carries what remains of the obligation.

Dropped by OQ-24. The answer went the other way, so nothing here is waiting on anybody and nothing arrives later.

The requirement was to show publicly disclosed industry payments. OQ-28 removes payment data from this product entirely, so there is nothing to show and nothing pending. The reasoning is on the record: US government guidance of 2020 warns against choosing paid speakers by past or expected sales, and a product that surfaced payment history beside a fit score would be building exactly that selection. NP-09 goes further in the same direction: no conflict-of-interest field, flag or note anywhere.

Dropped by OQ-28. The answer went the other way, so nothing here is waiting on anybody and nothing arrives later.